Background Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and
the prolonged use of glucocorticoids is associated with side effects. The effect of the …

Purpose Trials of tocilizumab in patients with severe COVID-19 pneumonia have
demonstrated mixed results, and the role of tocilizumab in combination with other treatments …

Objective Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of
Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib …

Objective Compare changes in lipids and lipid-associated cardiovascular (CV) risk markers
in patients with rheumatoid arthritis (RA) treated with tocilizumab or adalimumab. Methods …

Objective To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of
Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA). Methods …

Objective Corticosteroids (CS) are standard treatment for giant cell arteritis (GCA), but
concerns persist over toxicities associated with long-term use. In this retrospective study of …

Objective Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large
and medium-sized arteries. High-dose oral glucocorticoids (GCs) are the mainstay of GCA …

Objective This study was undertaken to evaluate glucocorticoid dosages and serologic
findings in patients with giant cell arteritis (GCA) flares. Methods Patients with GCA were …

Objective To report entry criteria and clinical features of patients with newly diagnosed and
relapsing giant cell arteritis (GCA) enrolled in a randomized trial of tocilizumab, an …

Introduction Treatment of giant cell arteritis (GCA) involves immediate initiation of high-dose
glucocorticoid therapy with slow tapering of the dose over many months. Chronic exposure …